A Phase I/II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naive, Recurrent Glioblastoma
Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
Sponsor: BMS & Novocure
Enrolling: Male and Female Patients
IRB Number: AAAS4043
U.S. Govt. ID: NCT03430791
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: In this research study, we are looking for Information on how well nivolumab with or without ipilimumab works in combination with TTFields in adult patients with glioblastoma. You will receive the Nivolumab and/or Ipilimumab study treatment until you decide to stop study treatment or your study doctor decides to remove you from the study. This means that you can stay on the study as long as there are no unmanageable risks. After you finish your study treatment, the study doctor will continue to watch you for side effects and follow your condition for 3 years.
This study is closed
Fabio Iwamoto, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Have you been diagnosed with glioblastoma? Yes No
Have you previously received radiation and temozolomide therapies? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator